Finch Therapeutics

What Finch Therapeutics does

Finch Therapeutics is a clinical-stage microbiome therapeutics company founded in 2014 (reorganized in 2017 via merger with Crestovo) and headquartered in Boston/Somerville, Massachusetts. The company develops donor-derived microbiome therapeutics targeting serious unmet medical needs, with its lead asset CP101 — an orally administered microbiome therapeutic designed to prevent recurrent Clostridioides difficile infection (CDI) in adults. The platform applies supervised machine learning to human microbiome data and leverages a universal donor model pioneered by co-founder Mark Smith, PhD, through the affiliated stool bank OpenBiome, which has treated more than 55,000 patients across a network of over 1,200 hospitals.

The company's underlying technology rests on insights from human microbiota transplantation studies spanning hundreds of third-party clinical studies, combined with proprietary preservation and oral delivery methods exclusively licensed from the University of Minnesota. Finch holds an intellectual property estate of 160 issued patents and more than 140 pending applications, including foundational patents in fecal floral transplantation, microbiome-related immunotherapies, and treatments for autism spectrum disorder, ulcerative colitis, Parkinson's disease, and other conditions. Additional pre-clinical assets include FIN-524 (ulcerative colitis), FIN-525 (Crohn's disease), and FIN-211 (autism spectrum disorder).

Finch Therapeutics operates as a pre-revenue biotech. It reported positive Phase 2 data for CP101 in 2020 and 2021 but discontinued its Phase 3 PRISM4 trial in January 2023. The company subsequently delisted from Nasdaq and deregistered with the SEC in October 2024, and in May 2026 filed for Chapter 11 bankruptcy protection to facilitate an outright sale, with resolution expected in early June 2026. The bankruptcy filing is structured to monetize the company's IP estate and litigation claims, including a claim against Ferring Pharmaceuticals. Total disclosed equity funding of approximately $188.8 million was raised across multiple rounds between 2016 and 2020.

Name

Finch Therapeutics

Legal name

Finch Therapeutics Group, Inc.

Website

https://finchtherapeutics.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Finch Therapeutics is a pre-revenue microbiome therapeutics company developing donor-derived oral microbiome products, with lead candidate CP101 targeting recurrent C. difficile infection. Now in Chapter 11 to facilitate an outright sale.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products (HLAAAFAE)

akta.pro secondary industries

Consortia & Defined Microbial Community Therapeutics (HLAAAFAC), Microbiome & Metagenomics Services (HLAGANAH), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)

Keywords

• Microbiome therapeutics
• Gut microbiome drugs
• Oral microbiome therapy
• C. difficile treatment
• Microbiome drug development

Headquarters

HQ city

Somerville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Clinical Development and Asset Monetization: Pre-revenue biotech company that discontinued its Phase 3 trial of CP101 in January 2023. The company is now focused on realizing the value of its IP estate and other assets through a Chapter 11 sale process, including patent portfolio monetization and litigation claims.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Finch Therapeutics developed CP101, an investigational orally administered microbiome therapeutic designed to prevent recurrent C. difficile infection by restoring a diverse microbial community in the gut. The company also held preclinical microbiome assets (FIN-524 for ulcerative colitis, FIN-525 for Crohn's disease, FIN-211 for autism spectrum disorder). Following the discontinuation of its Phase 3 PRISM4 trial in January 2023, Finch is now focused on realizing the value of its intellectual property estate and other assets through a Chapter 11 sale process.

Product overview

Finch Therapeutics is an early pioneer in the microbiome field with a portfolio of innovative microbiome assets. The core product is CP101, a late-stage investigational orally administered microbiome therapeutic for the prevention of recurrent C. difficile infection. The company also holds preclinical assets including FIN-524 for ulcerative colitis, FIN-525 for Crohn's disease, and FIN-211 for autism spectrum disorder. In January 2023, Finch discontinued its Phase 3 trial of CP101 and shifted focus to realizing the value of its intellectual property estate and other assets including a litigation claim against Ferring Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

• CP101 Investigational orally administered microbiome therapeutic designed to restore a diverse microbial community in the gut to help prevent recurrent C. difficile infection in adults who have failed standard antibiotic treatments.
• FIN-524 Pre-clinical microbiome asset designed to target ulcerative colitis as part of Finch's broader inflammatory bowel disease portfolio.
• FIN-525 Pre-clinical microbiome asset designed to target Crohn's disease as part of Finch's broader inflammatory bowel disease portfolio.
• FIN-211 Pre-clinical microbiome asset designed to address gastrointestinal and behavioral symptoms associated with autism spectrum disorder in children.

Quantifiable outcome

• Phase 2 trial demonstrated efficacy for prevention of recurrent C. difficile infection
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Centre for Digestive Diseases (Dr. Thomas Borody)coreStrategic or Co-development Partner · 1 January 2017Collaboration with Dr. Thomas Borody, founder of the Centre for Digestive Diseases in Australia, who began treating patients with microbiota transplantation in 1988 and filed foundational patents in 2010. Borody has published 59 case reports and carried out thousands of microbiota transplantations, helping catalyze microbiome research globally.
• OpenBiomecoreStrategic or Co-development PartnerOpenBiome was founded by MIT graduate students in 2012 as the nation's first public stool bank. Its founders later started Finch Therapeutics to further scale efforts to harness therapeutic potential of the microbiome. OpenBiome has treated 55,000+ patients through a network of 1,200+ hospitals.

Scale indicators5 records

Recent moves8 records

Expansion highlights2 records

Direct peers

• Seres Therapeutics: Clinical-stage microbiome therapeutics company developing SER-109 (now VOWST) for recurrent C. difficile infection. Direct competitor to Finch in the same indication and modality, with overlapping IP and target patient population.
• Vedanta Biosciences: Microbiome therapeutics company developing defined bacterial consortium products for C. difficile and other indications. Directly comparable to Finch's CP101 program as both develop orally administered microbiome candidates.
• Rebiotix (Ferring subsidiary): Developer of RBX2660 (now REBYOTA), the first FDA-approved fecal microbiota product. Direct FMT competitor to Finch's CP101 in recurrent C. difficile infection.

Emerging players

• Assembly Biosciences: Biotech developing microbiome-based therapies for serious diseases. Comparable as a small-cap clinical-stage company with overlapping therapeutic areas in gastrointestinal disorders.
• MaaT Pharma: European clinical-stage microbiome therapeutics company developing standardized fecal microbiota products for oncology and infectious disease indications. Comparable as a peer in FMT-based therapeutic development.
• BiomX: Clinical-stage microbiome company developing phage-based therapeutics. Adjacent in the microbiome therapeutics space with similar small-cap, clinical-stage profile.
• 4D Pharma: UK-based microbiome therapeutics company developing live biotherapeutics across multiple indications. Comparable as a peer in developing novel microbiome-derived therapeutic products.
• Second Genome: Microbiome drug discovery company using machine learning to identify bacterial targets. Overlaps with Finch's ML-driven platform approach to microbiome therapeutic development.
• Evelo Biosciences: Clinical-stage company developing oral microbiome-based therapies for inflammatory diseases. Comparable therapeutic area overlap (inflammatory conditions) and small-cap clinical-stage profile.

Broad incumbents

• Ferring Pharmaceuticals: Acquired Rebiotix and markets REBYOTA, an FDA-approved fecal microbiota product for recurrent C. difficile. Larger established pharma incumbent operating in the same therapeutic area and subject of Finch's ongoing litigation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/finch_tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Finch Therapeutics